OrthoLogic to Present at 23rd Annual JPMorgan Healthcare Conference

    Business Editors/Health/Medical Writers

    TEMPE, Ariz.--(BUSINESS WIRE)--Jan. 4, 2005--OrthoLogic Corp. (Nasdaq:OLGC) announced today that Thomas R. Trotter, president and CEO, and James T. Ryaby, Ph.D., senior vice president of research and clinical affairs and chief technology officer, will present at the 23rd Annual JPMorgan Healthcare Conference, to be held at the Westin St. Francis Hotel in San Francisco on Thursday, Jan. 13, 2005, at 1 p.m. PST.
    Trotter and Ryaby will provide an update on the development of the company's Chrysalin(R) Product Platform.
    To access the conference webcast, please visit http://equityconferences.jpmorgan.com and select the JPMorgan Healthcare Conference webcast link. After registering, click on the "Live Webcast" link and then click on OrthoLogic's name. The webcast will be archived beginning 24 hours after the live event and continue for 3 months.
    The webcast will also be archived on the Investor Relations page of OrthoLogic's Web site at www.orthologic.com.

    About OrthoLogic Corp.

    OrthoLogic is a drug-development company focused on commercializing several potential therapeutics comprising the Chrysalin(R) Product Platform, a series of product candidates aimed at treating traumatic and chronic orthopedic indications in bone and soft tissue as well as oral/maxillofacial bone repair, cardiovascular repair and wound healing. All of these potential products are based on the Chrysalin synthetic peptide, also known as TP508.
    OrthoLogic owns an exclusive license for all worldwide medical indications for the peptide, and is actively pursuing five orthopedic indications for Chrysalin. These include fracture repair and spine fusion, which are in human clinical trials, and cartilage defect repair, which is in late-stage preclinical trials. Ligament and tendon repair indications are in the preclinical studies stage. In non-orthopedic areas, a human clinical trial for chronic diabetic ulcers has been completed. OrthoLogic's product development pipeline also includes Chrysalin-based product candidates for dental bone formation and myocardial revascularization.

--30--KG/np*

CONTACT: OrthoLogic Corp. Thomas R. Trotter, 602-286-5500 or The Berlin Group Lawrence Delaney Jr., 714-734-5000

KEYWORD: ARIZONA INDUSTRY KEYWORD: MEDICAL BIOTECHNOLOGY PRODUCT SOURCE: OrthoLogic Corp.

Copyright Business Wire 2005